What disease is indicated by the finding of CD15 + CD30?

Prepare for USMLE Step 1 Pathology Exam with comprehensive quizzes, flashcards, and detailed explanations. Enhance your understanding and be exam-ready!

Multiple Choice

What disease is indicated by the finding of CD15 + CD30?

The finding of CD15+ and CD30+ markers in a patient is indicative of Hodgkin's Lymphoma. These markers are characteristic of Reed-Sternberg cells, which are the neoplastic cells central to the pathogenesis of Hodgkin's Lymphoma. CD15 is a cell adhesion molecule that is usually expressed on granulocytes, but in the context of Hodgkin's Lymphoma, it plays a key role in identifying the Reed-Sternberg cells. Similarly, CD30 is a member of the tumor necrosis factor receptor superfamily and its expression is also typically associated with Reed-Sternberg cells. The presence of both markers helps to confirm the diagnosis of Hodgkin's Lymphoma, distinguishing it from other hematologic malignancies. In contrast, Non-Hodgkin's Lymphoma encompasses a diverse group of cancers and does not specifically express CD15 or CD30 as defining features. Chronic Lymphocytic Leukemia primarily involves the proliferation of small, mature B-lymphocytes and is characterized by different surface markers, particularly CD5 and CD23. Multiple Myeloma, which is a malignancy of plasma cells, typically expresses markers such as CD38 and CD138, but neither CD15 nor

The finding of CD15+ and CD30+ markers in a patient is indicative of Hodgkin's Lymphoma. These markers are characteristic of Reed-Sternberg cells, which are the neoplastic cells central to the pathogenesis of Hodgkin's Lymphoma.

CD15 is a cell adhesion molecule that is usually expressed on granulocytes, but in the context of Hodgkin's Lymphoma, it plays a key role in identifying the Reed-Sternberg cells. Similarly, CD30 is a member of the tumor necrosis factor receptor superfamily and its expression is also typically associated with Reed-Sternberg cells. The presence of both markers helps to confirm the diagnosis of Hodgkin's Lymphoma, distinguishing it from other hematologic malignancies.

In contrast, Non-Hodgkin's Lymphoma encompasses a diverse group of cancers and does not specifically express CD15 or CD30 as defining features. Chronic Lymphocytic Leukemia primarily involves the proliferation of small, mature B-lymphocytes and is characterized by different surface markers, particularly CD5 and CD23. Multiple Myeloma, which is a malignancy of plasma cells, typically expresses markers such as CD38 and CD138, but neither CD15 nor

More practice questions